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Research Article
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SARS-CoV-2 is responsible for COVID-19, a human disease that has caused over 2
million deaths, stretched health systems to near-breaking point and endangered econ-
omies of countries and families around the world. Antiviral treatments to combat COVID-
19 are currently lacking. Remdesivir, the only antiviral drug approved for the treatment of
COVID-19, can affect disease severity, but better treatments are needed. SARS-CoV-2
encodes 16 non-structural proteins (nsp) that possess different enzymatic activities with
important roles in viral genome replication, transcription and host immune evasion. One
key aspect of host immune evasion is performed by the uridine-directed endoribonu-
clease activity of nsp15. Here we describe the expression and purification of nsp15
recombinant protein. We have developed biochemical assays to follow its activity, and we
have found evidence for allosteric behaviour. We screened a custom chemical library of
over 5000 compounds to identify nsp15 endoribonuclease inhibitors, and we identified
and validated NSC95397 as an inhibitor of nsp15 endoribonuclease in vitro. Although
NSC95397 did not inhibit SARS-CoV-2 growth in VERO E6 cells, further studies will be
required to determine the effect of nsp15 inhibition on host immune evasion.
Introduction
SARS-CoV-2 (severe-acute-respiratory-syndrome coronavirus-2) is the coronavirus that causes the
human coronavirus disease (COVID-19) [1,2]. SARS-CoV-1 and MERS-CoV caused severe diseases in
2003 and 2012, respectively, and, although their consequences in terms of worldwide loss of human
life cannot be compared with the devastating health and economic crisis caused by COVID-19 pan-
demic, the emergence of SARS-CoV-2 indicates a pattern of recurrent coronavirus diseases with rele-
vance for human health [3,4]. Some features of SARS-CoV-2 have been pinpointed as key to explain
the catastrophic consequences of COVID-19; an easy air-transmissibility, a large percentage of asymp-
tomatic infections, and the ability of the virus to infect multiple cell types and organs and deregulate
the immune system [5–9].
In a major international effort, multiple vaccines are being developed and several are already being
administered. It is still uncertain whether vaccines will fully prevent future infections or lead to milder
COVID-19 infections [10]. Most vaccines are being developed against the spike protein of the virus, a
structural protein that evolves rapidly and, therefore, might not be a long-term solution to COVID-19
and, moreover, is unlikely to provide a pan-coronavirus solution [11,12]. There is currently a lack of
antiviral treatments that efficiently combat coronavirus infections. Remdesivir, a nucleotide analogue
chain terminator proven to reduce viral growth, is the only antiviral approved for the treatment of
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COVID-19 [13]. However, a WHO-funded clinical trial recently failed to demonstrate a reduction in deaths
amongst patients treated with remdesivir [14]. Therefore, the further development of efficient antiviral treat-
ments to combat diverse coronavirus infections will remain important for health systems worldwide to face
present and future coronavirus pandemics.
SARS-CoV-2 is a (+) single-strand RNA virus that belongs to the family Coronaviridae of the order Nidovirales,
which includes viruses with the largest known RNA genomes [15–17]. The first two-thirds of the genome encode
two open-reading frames, ORF1a and ORF1b, that are directly translated from the viral genome producing two
large polyproteins (pp1a and pp1ab) that contain the 16 non-structural proteins (nsps) of the virus. These poly-
proteins are cleaved by the proteolytic activities of nsp3 and nsp5, which therefore modulate the activity of the
rest of the enzymes and promote the formation of active protein complexes including the RNA-dependent RNA
polymerase (nsp12/nsp7/nsp8), the RNA helicase (nsp13), the RNA exoribonuclease (nsp14/nsp10), the RNA
endoribonuclease (nsp15) and the RNA Cap methyltransferases (nsp14 and nsp16/nsp10), which together
support proliferation of the virus. Therefore, coronaviruses contain a wide variety of enzymes that are potential
targets for the development of novel antivirals, by comparison with many other viruses.
nsp15 contains a C-terminal ‘EndoU’ domain (endoribonuclease uridylate-specific) that is able to cleave the
30 end of pyrimidines, preferentially uridylates, in the context of single and double-stranded RNA molecules
[18–21]. Purified nsp15 can exist as an inactive monomer or trimer, or an active hexamer [22,23].
Oligomerisation relies on N-terminal residues of nsp15 and activity is dependent on the presence of divalent
metal ions, with a preference for Mn2+ [19,23,24]. The EndoU activity of nsp15 is dispensable for replication of
viral RNA genome [20,25]. Instead, nsp15 EndoU activity appears to mediate the evasion of host recognition of
viral dsRNA, and growth of EndoU-deficient viruses is severely affected in mouse models and primary immune
cells such as macrophages [21,26,27]. Therefore, nsp15 EndoU inhibitors might be useful to potentiate the host
immune response to SARS-CoV-2.
In March 2020, we initiated a large project to identify inhibitors of multiple SARS-CoV-2 enzymes from a
custom chemical library containing over 5000 compounds. Here we describe the results of a screen for nsp15
endoribonuclease inhibitors.
Results
Purified SARS-CoV-2 nsp15 has uridylate-specific endoribonuclease activity
in vitro
We expressed and purified a series of N-terminally tagged versions of nsp15 from bacteria and insect cells
(Figure 1A). Nsp15 eluted as a high molecular weight complex during size-exclusion chromatography, consist-
ent with nsp15 existing as a hexamer [22,23] (Supplementary Figure S1A). Removal of the affinity tags with
proteases was generally inefficient, consistent with a recent structural study that showed that the N-terminus of
nsp15 is not on the surface of the nsp15 hexamer [28]. After partial digestion of 14His-SUMO-nsp15 with
Ulp1 SUMO protease, untagged nsp15 eluted much later during size-exclusion chromatography, suggesting the
untagged protein was primarily present in a smaller complex or as a monomer (Supplementary Figure S1A,B).
To evaluate nsp15 endoribonuclease activity, we used a 16 nt single-stranded RNA substrate labelled with a
Cy3 fluorophore, which contained a single uridine near the centre (Figure 1B). N-terminal MBP-,
14His-SUMO-, 6His- and 3xFlag-6His- tagged versions of nsp15 were able to cleave this substrate, whereas the
nsp15-2A mutant in which two key Histidine residues (H234A H249A) were replaced with alanine, did not
[29] (Figure 1C). Notably, untagged nsp15 generated from the digestion of 14His-SUMO-nsp15, was inactive
as an endoribonuclease consistent with the idea that only the hexameric form of nsp15 is active [22,23,30]. We
selected 6His-nsp15 for use in subsequent screening and validation assays. Whilst this enzyme was active on
the uridylate-containing substrate, it had no detectable activity on a substrate in which the single uridine was
substituted for cytidine (Figure 1D). Taken together, these results show that the purified 6His-nsp15 possesses
uridylate-specific endoribonuclease activity, consistent with previous data [22,23,30].
Assay to study kinetic SARS-CoV-2 nsp15 endoribonuclease activity in
solution
To perform a high-throughput screen for inhibitors of nsp15, we first developed an assay to quantify nsp15
endoribonuclease activity in solution without the need to visualise products in a gel. We used a short (6 nt)
single stranded RNA oligonucleotide containing a single uridine and a 50 Cy5 that was quenched by proximity
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to a 30 BBQ-650 quencher. This substrate only exhibits fluorescence upon cleavage by nsp15, when the Cy5 is
no longer in proximity to the quencher (Figure 2A). We found that nsp15 was able to cleave the 16 nt
(Figure 2B, top) and 6 nt (Figure 2B, bottom) substrates at similar enzyme concentrations. As expected, fluores-
cent signal from the 3 nt cleavage product was only detectable upon substrate cleavage. The uridylate specificity
of nsp15 was confirmed again by its lack of activity on a 6 nt substrate containing cytidine in place of uridine
(Figure 2C).
Prior to performing the screen to identify inhibitors of SARS-CoV-2 nsp15, we adapted the in-solution fluor-
escent biochemical assay to a multi-well plate format. We first performed a titration of nsp15 and were able to
detect Cy5 fluorescence on a plate reader in a time and enzyme concentration-dependent manner (Figure 2D).
As seen in gel-based assays, nsp15 exhibited reduced endonuclease activity toward the C substrate when using
the plate reader (Figure 2E) and, accordingly, the nsp15-2A catalytically inactive mutant did not produce fluor-
escent signal on either substrate (Figure 2F). In parallel, the nuclease RNase A showed efficient cleavage of
both substrates (Figure 2G). As the compounds in the chemical library to be used for the screen were stored in
DMSO, we also tested nsp15 activity in the presence of DMSO and found DMSO at concentrations up to 5%
had only a slight inhibitory effect on enzyme activity (Figure 2H).
Fluorescent biochemical kinetic screen for SARS-CoV-2 nsp15 inhibitors
We next used this assay to determine the effect of substrate concentration on initial reaction velocities. We
found that, in contrast with all of the other enzymes we have examined in this series of papers [31–36], reac-
tion rates did not plateau at higher substrate concentrations but instead continued to increase non-linearly,
indicating that nsp15 endoribonuclease behaves as an allosteric enzyme towards the 6 nt U substrate, with a
Khalf of 2140 nM (Figure 3A and Supplementary Figure S2A).
We performed the screen with 75 nM nsp15 enzyme and 500 nM substrate, which produced reactions that
were linear over the 15 min of reaction monitoring, against a library of over 5000 commercial compounds (see
Zeng et al. [31] for contents and description of the custom chemical library). These compounds were dispensed
in DMSO over 24 384-well plates, and we tested two concentrations: 1.25 mM (low) and 3.75 mM (high). For
the screen, we dispensed the nsp15 enzyme and incubated it with the drugs at room temperature (RT) for
10 min, after which we dispensed the substrate and started monitoring Cy5 fluorescence every minute for
15 min (Figure 3B and Supplementary Figure S2B). We included extra wells in every plate to control for any
change in enzyme kinetics that could affect the identification of inhibitors (Supplementary Figure S2B). The Z0
factor was calculated for each plate, and the average Z0 factor for the whole screen was 0.8 indicating a high-
quality screen (Supplementary Figure S2C). One plate of the high compound concentration had a Z0 factor
<0.5 and was omitted from analysis.
Reaction slopes in the presence of each compound were calculated and normalised to the DMSO-containing
positive controls (control reactions) on each plate (Figure 3C and Supplementary Figure S2B). We did not find
any inhibitors that showed residual activities <0.7 in both concentrations (Figure 3D), which was surprising
given the results of similar screens from our accompanying manuscripts [31–37]. Therefore, we considered
compounds that had residual activities <0.9 and had a Z-score <−4 (Figure 3E and Supplementary
Figure S2D). We also considered hits that decreased activity further in the high concentration than the low con-
centration, even if both residual activities were not below our cut-offs.
Validation of hits
We selected 17 compounds of the top hits from the screen for further analysis (Supplementary Table S3). We
performed a test to determine if any of the 17 compounds quenched Cy5 fluorescence. Four compounds (in
red) quenched Cy5 fluorescence in a concentration-dependent manner (Supplementary Figure S3). We then
assessed inhibition of nsp15 endoribonuclease activity with the 12 remaining compounds using the plate reader
(Supplementary Figure S4). Only NSC95397 and BMS-1166 compounds were able to inhibit nsp15 endoribo-
nuclease activity at 10 mM (Figure 4A and Supplementary Figure S4). To explore inhibition by the top hit com-
pounds further, we returned to the gel-based assay and assessed nsp15 endoribonuclease activity using the
16 nt substrate (Figure 4B). Again, NSC95397 (drug 10) inhibited nsp15 endoribonuclease. BMS-1166 did not
inhibit the enzyme even at 100 mM in the gel-based assays. GNF-PF-3777 (drug 6) had been chosen for its
high score as a putative activator of nsp15 (Supplementary Table S3) but had no effect even at 100 mM in the
gel-based assays (Figure 4B). WEHI-539 hydrochloride (drug 1), selected from the screen as a putative nsp15
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inhibitor and later found to quench Cy5 fluorescence (Supplementary Figure S3), enhanced nsp15 endoribonu-
clease activity in the gel-based assay (Figure 4B).
To study the specificity of NSC95397 towards nsp15, we tested whether RNase A and benzonase nuclease
activities were inhibited by NSC95397. Increasing amounts of NSC95397 inhibited nsp15 endoribonuclease
activity but did not affect nuclease cleavage by RNaseA and benzonase, indicating that NSC95397 is not a
general nuclease inhibitor (Figure 4C).
To determine the range of concentration of NSC95397 able to inhibit nsp15 endoribonuclease, we titrated
NSC95397 and estimated the IC50 (43 mM) of NSC95397 inhibition of nsp15 endoribonuclease (Figure 4D,E).
Effects of NSC95397 on SARS-CoV-2 growth in VERO E6 cells
Previous work has suggested that nsp15 activity plays a role in host recognition and response and is dispensable
for viral replication and growth [21,25,27]. However, another study found that nsp15 inhibitors reduced
SARS-CoV-1 viral growth in VERO E6 cells [38]. The compounds they used inhibited nsp15 endoribonuclease
activity in vitro, but they also inhibited other ribonucleases. So, these results could be explained by inhibition
of nsp15 or other viral or host RNases. Since the compound from our screen, NSC95397, selectively inhibited
nsp15 and not RNase A or benzonase, we used NSC95397 to determine whether specific inhibition of nsp15
reduces SARS-CoV-2 viral growth in VERO E6 cells.
We infected VERO E6 cells with SARS-CoV-2 in the presence of a range of concentrations of NSC95397
and quantified viral infected area (Figure 5A,B). NSC95397 sacrificed VERO E6 cells at concentrations above
10 μM, consistent with previous reports that NSC95397 is an inhibitor of the Cdc25 protein phosphatase and
multiple protein kinases [39–42]. This made it more difficult to assess viral growth. With the aim of finding a
concentration of NSC95397 that inhibited viral growth without killing the cells, we performed a second titra-
tion at lower NSC95397 concentrations (Figure 5C,D). Cell survival was much less impacted, but viral growth
was not inhibited by NSC95397 (Figure 5C,D).
Mutation of the exoribonuclease activity of nsp14 has been shown to sensitise SARS-CoV-1 to the antiviral
agent remdesivir [43]. To explore if inhibition of the nsp15 endoribonuclease activity also synergised with
remdesivir antiviral activity, we performed infectivity assays in the presence of both NSC95397 and remdesivir.
However, we did not observe any additive effect of these two drugs on SARS-CoV-2 infectivity in VERO E6
cells (Figure 5E,F).
Discussion
We have purified SARS-CoV-2 nsp15 enzyme and optimised fluorescent biochemical endoribonuclease
(EndoU) assays to screen a custom chemical library containing over 5000 characterised commercial com-
pounds. We identified NSC95397 as a novel nsp15 EndoU inhibitor in vitro. The role of nsp15 endoribonu-
clease during SARS-CoV-2 proliferation is still unclear [18,20,21,25,44]. Coronaviruses with mutated nsp15 are
viable in viral replication assays yet have severe growth defects in immune specialised cell models such as
macrophages and in immune proficient mouse models, indicating an essential role for nsp15 in mediating the
evasion of the host immune system [21,26,27,45,46]. Indeed, nsp15 has been shown to antagonise the produc-
tion of interferon beta, and thus its inhibition might lead to increased interferon production [47]. Macrophages
and other immune cells can become infected with SARS-CoV-2 in human patients, and lung macrophage dys-
function has been associated with severe COVID-19, consistent with a key role for macrophages in the early
immune response to combat SARS-CoV-2 infections [48–50]. Therefore, the use of nsp15 inhibitors would
appear to be an attractive strategy to boost immune recognition of the virus at early stages of infection.
NSC95397 is an inhibitor of Cdc25 phosphatase and of multiple kinases [39–42]. It has been reported to modu-
late the expression of immune molecules and to have anticancerogenic effects [51,52]. NSC95397 has also been
shown to have antiviral effects, as it has been associated with increased interferon beta production and reduced
growth of Influenza virus in mouse models [53]. Although NSC95397 inhibited nsp15 activity in vitro, it did not
impair the proliferation of SARS-CoV-2 in VERO E6 cells, which are a commonly used host cells for viral growth
under laboratory conditions. However, VERO E6 are derived from the Green Monkey Chlorocebus sabaeus, and it
will be important in future studies to establish better cellular models with which to assess the importance of nsp15
for the evasion of host immune responses during SARS-CoV-2 infection of appropriate human cells.
Being an endoribonuclease, unrestricted nsp15 activity might lead to unwanted cleavage of the viral genome,
so regulation of its activity is likely to be important for balancing its immune evasion function with viral
genome integrity. One level of regulation of nsp15 activity is at the substrate level where nsp15 shows
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).2468
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differential activity towards sequences surrounding the targeted uridylate, as well as RNA secondary structures
and modifications such as 20-O-methyl groups [18,54]. The formation of the nsp15 active hexamer could be
another level of regulation [55]. Because nsp15 is only active as a hexamer, it is likely that nsp15 activity is
restricted to later steps of infection when enough nsp15 has been translated to support hexamer formation.
Our results show that nsp15 activity is stimulated at high substrate concentrations, indicating that nsp15 is an
allosteric enzyme (Figures 2, 3A and Supplementary Figure S2A), which confirms predictions based on struc-
tural cryo-EM studies of the SARS-CoV-2 nsp15 hexamer [23]. This allosteric behaviour might serve as an add-
itional control to limit nsp15 EndoU activity and locally protect the viral RNA. Thus, nsp15 activation might
occur at later times post infection, where the virus has produced enough nsp15 protein and substrate.
Accordingly, in our screen we used high enzyme and substrate concentrations (75 nM nsp15 and 500 nM sub-
strate). However, this high enzyme concentration combined with high substrate competition (for potential
competitive inhibitors) might explain why we did not detect many compounds able to inhibit nsp15 EndoU
activity, and why our hit compounds only reduced nsp15 activity by 10–20% in the original conditions of the
screen. We and our colleagues were able to detect hits for the other SARS-CoV-2 enzymes using the same drug
library and general screening strategy (see accompanying manuscripts [31–37]) and, therefore, it would be
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Figure 1. Purification of active SARS-CoV-2 nsp15 endoribonuclease.
(A) A range of affinity tags were used to purify nsp15. Purified proteins were visualised by SDS–PAGE and Coomassie Blue
staining. ‘untagged’ nsp15, which was generated by partial proteolytic cleavage of 14His-SUMO nsp15 with Ulp1 SUMO
protease, eluted much later during size-exclusion chromatography, consistent with the untagged nsp15 existing as a smaller
complex or monomer (see Supplementary Figure S1). 6His (2A) protein corresponds to the H234A H249A mutant of nsp15.
(B) Scheme of the gel-based endoribonuclease assay for nsp15. A 16 nt ssRNA containing a 50 Cy3 fluorophore (16 nt U
substrate) is cleaved at the only uridine (U) to yield a 10 nt product. A version of this substrate with a cytosine instead of uridine
is used to test specificity of nsp15 cleavage in D (16 nt C substrate). (C) Cleavage of the 16 nt U substrate by the different
purified nsp15 proteins shown in A. 100 nM of nsp15 and 1 mM of substrate were incubated for 30 min at 30°C and then
resolved in a denaturing TBE-urea polyacrylamide gel. Quantification of the percent product in the cleaved 10 nt band is given
at the bottom of the gel. (D) The U or C version of the 16 nt substrate (1 mM) were incubated with different concentrations of
wild-type (WT) or 2A-endoribonuclease mutant 6His-nsp15, and endonuclease reactions were performed as in C.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 2469
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We found that NSC95397 is an inhibitor of nsp15 but not a general nuclease inhibitor in vitro. We looked
for compounds previously shown or predicted to inhibit nsp15 in our library and found that, although none
passed our cut-off, some of them also inhibited nsp15 to some degree in our screen (Supplementary Table S4)
[38,56–58]. Previous studies have found nsp15 to be sensitive to RNase A inhibitors [38], so, interestingly, our
data would suggest that NSC95397 inhibits nsp15 through a different mechanism (Figure 4C). In addition,
though our infectivity assays using VERO E6 cells did not find NSC95397 to be effective in inhibiting
SARS-CoV-2 viral growth, RNase A inhibitors did reduce SARS-CoV-1 viral growth in VERO cells [38]. This
could be due to RNase A inhibitors also inhibiting the other nuclease in coronaviruses, nsp14, or it could be
that the higher viral load and later timepoint of infection used in that study compared with our infectivity
assays could have been more sensitive to nsp15 inhibition. In agreement with a late infection role for nsp15,
nsp15 can specifically cleave the polyuridine tracks of the later transcribed negative-strand RNA strand of the
virus, which could lead to reducing the activation of cytosolic immune sensors [45]. Future studies could assess
the effects of NSC95397 with late infection conditions, in appropriate human immune cells or in mouse
models, which, as discussed above, are sensitive to mutations of nsp15 EndoU activity. In addition, our assays
showed high host cell toxicity in response to NSC95397, so it would also be interesting to test fluorinated and
hydroxylated derivatives of NSC95397, which have been proposed to be less toxic [59].
Because of its role in immune evasion, treatment with nsp15 inhibitors could be useful early in SARS-CoV-2
infection to help elicit a robust immune response to clear the virus. As an alternative strategy, nsp15 inhibitors
could be tested in combination with other treatments to screen for synthetic anti-viral effects. Our colleagues
have identified other SARS-CoV-2 enzyme inhibitors (see accompanying manuscripts [31–37]), and it would
be interesting to test multiple compounds in a ‘cocktail’ approach to treating COVID-19.
Experimental procedures
Expression constructs
We constructed four plasmids to express different tagging combinations of nsp15 in Escherichia coli (E.coli)
(Supplementary Tables S1, S2). SARS-CoV-2 nsp15 was codon optimised for bacterial expression (Genbank
MN908947.3) and cloned into BamHI-NotI MCS of pMEXCb vector (https://mrcppu-covid.bio/cdna-clones/
134146) to create plasmid SARS-CoV-2 MBP-nsp15 (DU67734). Plasmid SARS-CoV-2 14His-SUMO-nsp15
(MRC Id DU70489) was built by PCR with oligos 9142/9143 from DU67734 and Gibson assembly into
K27SUMO vector [60]. Plasmid SARS-CoV-2 6His-nsp15 (MRC Id DU70490) was built by PCR with oligos
9156/9157 from DU67734 followed by PCR digestion with NcoI and XhoI and ligation into pET28C. Plasmid
SARS-CoV-2 His-nsp15 (H234A H249A) (MRC Id DU70491) was built by PCR with oligos 9150/9151 from
DU70490.
Expression and purification of SARS-CoV-2 nsp15 in E. coli
Rosetta™ (DE3) pLysS cells (Novagen) (F- ompT hsdSB (rB- mB-) gal dcm (DE3) pLysSRARE (CamR) were
transformed with plasmid DU70490 to express 6His-nsp15. Transformant colonies were inoculated into a
400 ml LB/chloramphenicol (35 mg/ml) / kanamycin (50 mg/ml) and grown overnight at 37°C with shaking at
200 rpm. The next morning, the culture was mixed with 3600 ml of LB/chloramphenicol (35 mg/ml)/kanamy-
cin (50 mg/ml) and further grown at 37°C until OD600 reached 0.8. Protein expression was induced by addition
of 0.4 mM IPTG, and the culture was shaken overnight at 16°C. Cells were harvested by centrifugation at
5000 rpm for 10 min in a JLA-9.1000 rotor (Beckman). The bacterial pellet was resuspended in 20 ml lysis
buffer (50 mM Tris–HCl (pH 8), 0.5 M NaCl, 10 mM imidazole, 0.5 mM TCEP, Roche protease inhibitor
tablets) with 500 mg/ml lysozyme, then incubated at 4°C for 0.5 h with rotation. Subsequently, the sample was
sonicated twice for 90 s (15 s on, 30 s off ) at 40% on a Branson Digital Sonifier. After centrifugation at 15
000 rpm at 4°C for 0.5 h in an JA-30.50 rotor (Beckman), the obtained soluble extract was mixed with 2 ml
slurry Ni-NTA beads (30210, QIAGEN), incubated at 4°C for 2 h with rotation. Beads were recovered in a dis-
posable gravity flow column and washed with 150 ml of lysis buffer then 20 ml lysis buffer containing 10 mM
MgCl2 and 2 mM ATP (to remove bacterial chaperones) then 20 ml lysis buffer. Proteins were eluted with 5 ml
lysis buffer containing 0.4 M imidazole. The eluate was loaded onto a 120 ml Superdex 200 column in Gel fil-
tration buffer (50 mM Tris–HCl (pH 8), 0.15 M NaCl, 0.5 mM TCEP). Nsp15-containing fractions were
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).2470
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Figure 2. Development of a fluorescent biochemical nsp15 endoribonuclease assay. Part 1 of 2
(A) A 6 nt ssRNA containing a 50 Cy5 fluorophore quenched by a 30 BBQ-650 quencher (6 nt U substrate) was used to assess
the activity of nsp15 in gels-based assays and in solution. Upon addition of the nsp15 endoribonuclease, cleavage of the oligo
at its only uridine (U) releases the quencher, leading to Cy5 fluorescence. A version of this substrate with a cytidine in place of
the uridine (6 nt C substrate) is used to test the uridine specificity of nsp15 cleavage. (B) Titration of nsp15 enzyme in the
presence of 1 mM of the 16 nt U substrate (upper gel) or 1 mM of the 6 nt U substrate (lower gel) showing activity on both
substrates at similar enzyme concentrations. Reactions were performed for 30 min at 30°C and resolved in a denaturing
TBE-urea denaturing polyacrylamide gel. Fluorescence of the 6 nt substrate was only observed upon cleavage by nsp15.
Appearance of a fluorescent band above the 3 nt suggests that nsp15 can cleave the 6 nt substrate at more than one residue.
(C) The ‘U’ and ‘C’ version of the 6 nt substrate (1 mM) were incubated with different concentrations of wild-type (WT) or
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 2471








K user on 06 July 2021
pooled, concentrated to 0.6 mg/ml by ultrafiltration using Amicon Ultra centrifugal unit (30 k MWCO;
MERCK), aliquoted and snap frozen. An amount of 4 L of culture typically yielded 0.8 mg of 6His-nsp15.
The 6His-tagged H234A H249A nsp15 mutant was purified as described above. An amount of 1 L of culture
yielded 4.0 mg of 6His-nsp15 H234A 249A.
14His-SUMO-nsp15 was purified as for 6His-nsp15, except that we attempted to remove the 14His-SUMO
tag by overnight Ulp1 cleavage at 4°C before the gel filtration step. Proteolytic cleavage was partial, and the
resultant untagged nsp15 was subsequently separated from 14His-SUMO-nsp15 on a 120 ml Superdex 200
column equilibrated in gel filtration buffer (50 mM Tris–HCl (pH 8), 0.15 M NaCl, 0.5 mM TCEP). An
amount of 4 L of culture yielded 0.23 mg of 14His-SUMO-nsp15 and 0.18 mg of untagged nsp15.
For purification of MBP-nsp15, Rosetta™ (DE3) pLysS cells were transformed with plasmid DU67734
(pMEX3Cb SARS-CoV2 (2019-nCoV) NSP15). Transformant colonies were inoculated into 200 ml LB/chlor-
amphenicol (35 mg/ml)/ampicillin (100 mg/ml) and grown at 37°C with shaking at 200 rpm. After ∼10 h
growth, 100 ml of the culture was mixed with 900 ml of LB/chloramphenicol (35 mg/ml)/ampicillin (100 mg/
ml) and grown at 37°C until OD600 reached 0.8. The protein expression was induced by addition of 0.2 mM
IPTG, and the culture was shaken overnight at 18°C. Cells were harvested by centrifugation at 5000 rpm for
10 min in a JLA-9.1000 rotor (Beckman). The bacterial pellet was resuspended in 20 ml lysis buffer (50 mM
Tris–HCl (pH 8), 0.5 M NaCl, 0.5 mM TCEP, Roche protease inhibitor tablets) and lysed as described for
6His-nsp15. The clarified extract was mixed with 2 ml amylose beads and incubated at 4°C for 2 h with rota-
tion. Beads were recovered and washed as for 6His-nsp15. Proteins were eluted with 5 ml lysis buffer contain-
ing 10 mM maltose. The eluate was loaded onto a 120 ml Superdex 200 column in Gel filtration buffer (50 mM
Tris–HCl (pH 8), 0.15 M NaCl, 0.5 mM TCEP). Nsp15-containing fractions were pooled, concentrated by
ultrafiltration using Amicon Ultra centrifugal unit (30 k MWCO; MERCK), aliquoted and snap frozen. An
amount of 2 L of culture yielded 0.11 mg of MBP-nsp15.
Expression and purification of SARS-CoV-2 nsp15 in insect cells
The plasmid pBIG1a_3xFlag-6His-nsp15 (SARS-CoV-2) (Addgene Id 169166) was used to express
3xFlag-6His-predicted nsp5 cleavage site [SAVLQ]-nsp15 in baculovirus-infected insect cells (Supplementary
Tables S1, S2). The coding sequence of SARS-CoV-2 nsp15 (NCBI reference sequence NC_045512.2) was
codon-optimised for S. frugiperda and synthesised (GeneArt, Thermo Fisher Scientific). Nsp15 was subcloned
into a modified biGBac pBIG1a vector containing a pLIB-derived polyhedrin expression cassette [61] to
contain an N-terminal 3xFlag-His6 tag (sequence: MDYKDHDGDYKDHDIDYKDDDDKGSHHHHHHSAVLQ-
nsp15). Baculoviruses were generated and amplified in Sf9 cells (Thermo Fisher Scientific) using the EMBacY
baculoviral genome [62]. For protein expression Sf9 cells were infected with baculovirus, collected 48 h after
infection, flash-frozen, and stored at −70°C.Cell pellets were resuspended in pulldown buffer (30 mM HEPES pH
7.6, 250 mM sodium chloride, 5 mM magnesium acetate, 10% glycerol, 0.02% NP-40 substitute, 1 mM DTT)
supplemented with protease inhibitors (Roche Complete Ultra tablets, 1 mM AEBSF, 10 μg/ml pepstatin A,
10 μg/ml leupeptin) and lysed with a dounce homogenizer. The protein was purified from the cleared lysate by
affinity to Anti-FLAG M2 Affinity gel (Sigma–Aldrich) and eluted with pulldown buffer containing 0.1 mg/ml
3xFlag peptide. Eluate was further purified by gel filtration as described for the bacterially expressed proteins. An
amount of 0.5 L of culture yielded 0.8 mg of 3xFlag-His-nsp15.
Figure 2. Development of a fluorescent biochemical nsp15 endoribonuclease assay. Part 2 of 2
2A-endoribonuclease mutant 6His-nsp15 enzyme and endonuclease reactions were performed as in B. (D) Titration of nsp15
enzyme (0–200 nM nsp15) in the presence of 200 nM of the 6 nt U substrate performed at RT and fluorescence quantified in a
Spark Multimode microplate reader (Tecan) every minute for a total of 60 min. (E) Cleavage of the ‘U’ and ‘C’ versions of the
6 nt substrate (1 mM) in the presence of 500 nM nsp15. Reactions were performed at RT and fluorescence was measured in an
infinite M1000 Pro reader (Tecan) every minute for 45 min. (F) Same reactions as in E performed with 500 nM of nsp15-2A
mutant. (G) Same reactions as in E performed with 0.1 mg/ml RNase A. The graphs in panels E, G and F were separated for
visual clarity, but were done simultaneously and with common substrate master mixes. (H) Cleavage of the 6 nt U substrate
(500 nM) in the presence of 75 nM nsp15 and 0, 2.5% or 5% DMSO, and fluorescence measured in a Spark Multimode
microplate reader (Tecan) every minute for 45 min. Fluorescence of reactions containing substrate-only and enzyme-only
controls is also shown.
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Figure 3. SARS-CoV-2 endoribonuclease nsp15 inhibitor screen design and results.
(A) Non-linear fit to an Allosteric sigmoidal equation of the slopes calculated from the first 10 min of a titration of the 6 nt U
substrate (0–1000 nM) performed in the presence of 75 nM nsp15 (see Supplementary Figure S2A and Experimental
Procedures). (B) Scheme describing the reaction steps during the screen. (C) Residual activity of nsp15 in each sample well
containing a compound for the low (1.25 mM) and high (3.75 mM) concentration of compounds. (D) Comparison of residual
activities of sample wells between low and high concentration. (E) Comparison of Z-scores of each compound between low
and high concentration.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 2473
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Figure 4. NSC95397 inhibits SARS-CoV-2 nsp15 endoribonuclease activity in vitro. Part 1 of 2
(A) Normalised residual activity of nuclease reactions monitoring cleavage of the 6 nt U substrate (500 nM) in solution using a
Spark Multimode microplate reader (Tecan) in the presence of 75 nM of nsp15 and 10 mM of each of the 12 non-quenching
selected screen hits (Supplementary Figure S3). Residual activities were calculated for each compound from experiment shown
in Supplementary Figure S4, and normalised to control reaction. (B) Nuclease reactions containing 500 nM nsp15 enzyme and
1 mM 16 nt U substrate in the presence of 100 mM of each of the 17 selected screen hits. Reactions were performed for 20 min
at 30°C and resolved in a denaturing TBE-urea denaturing polyacrylamide gel. Control lanes include enzyme denaturation by
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SARS-CoV-2 nsp15 endoribonuclease assays
A 16 nt 50 Cy3-single stranded RNA (ssRNA) substrate (16 nt substrate) was used to monitor the nsp15 uridine-
dependent endoribonuclease activity in gel-based assays (Supplementary Table S2). A 6 nt 50 Cy5 and 30 BHQ650
quencher ssRNA substrate (6 nt substrate) was used to quantify nsp15 uridine-dependent endoribonuclease activ-
ity in gel-based assays (Figure 2B,C) and in solution using a Spark Multimode microplate reader (Tecan).
Figure 4. NSC95397 inhibits SARS-CoV-2 nsp15 endoribonuclease activity in vitro. Part 2 of 2
SDS and addition of water or DMSO, to mimic addition of drugs diluted either in water or DMSO. (C) Nuclease reactions
containing 500 nM nsp15, 1 pg/ml RNase A or 25 mU/ml Pierce Universal Nuclease (benzonase) and 1 mM 16 nt U substrate in
the presence of 0, 11, 33 or 100 mM NSC95397 inhibitor. Reactions were performed as in B. (D) Titration of NSC95397
inhibitor (0–100 mM) in the presence of 75 nM nsp15 enzyme and 500 nM 6 nt U substrate and fluorescence quantified in a
Spark Multimode microplate reader (Tecan) at RT every minute for 15 min. (E) Dose-response curves and IC50 values of
NSC95397 for SARS-CoV-2 nsp15. IC50 values were calculated as described in Experimental Procedures.



























































































Figure 5. NSC95397 does not inhibit SARS-CoV-2 growth in VERO cells.
(A) SARS-CoV-2 infectivity assays in the presence of NSC95397. DNA in cells was stained with DRAQ5, and virus was
immunostained with anti-N antibody. (B) Quantification of normalised viral area (black) and cell area (gray) ±SD. Both viral and
cell area was normalised to control condition (DMSO) and, viral area was also normalised to cell area (see Experimental
Procedures for details). (C) SARS-CoV-2 infectivity assays as in A with lower concentrations of NSC95397. (D) Quantification of
C as in B. (E) SARS-CoV-2 infectivity assays as in C in the presence of 0.5 mM remdesivir. (F) Quantification of E as in B, note
that black control line is quantification of control experiment in C.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 2475








K user on 06 July 2021
The assay, with either substrate, was performed by incubating the enzyme and the substrate at RT in total
20 ml in nsp15 reaction buffer (50 mM Tris–HCl pH 7.5, 50 mM NaCl, 10 mM MnCl2, 5 mM MgCl2, 0.1 mg/
ml BSA, 0.02% Tween-20, 10% glycerol and 0.5 mM TCEP). Specific enzyme and substrate concentrations as
well as duration of the reaction is indicated in the figure legends for each experiment.
High-throughput kinetic endoribonuclease screen
High-throughput screen was performed using a custom collection of over 5000 compounds from commercial
sources (Sigma, Selleck, Enzo, Tocris, Calbiochem, and Symansis). An amount of 2.5 or 7.5 nl of a 10 mM
stock of the compounds dissolved in DMSO were arrayed and dispensed into square flat-bottom black 384-well
plates containing 1 ml DMSO/well using an Echo 550 (Labcyte), before being sealed and stored at −80°C.
The day of the screen, plates were initially moved from −80°C to 4°C, then moved to RT for at least 30 min
prior to the screen. Plates were centrifuged and desealed just prior to dispensing 10 ml of 2× enzyme mix
(150 nM nsp15, 50 mM Tris–HCl pH 7.5, 50 mM NaCl, 10 mM MnCl2, 5 mM MgCl2, 0.1 mg/ml BSA, 0.02%
Tween20, 10% glycerol, 0.5 mM TCEP) using a XRD-384 Reagent Dispenser (FluidX Ltd.) or hand-pippetting
control columns (Figure 3B and Supplementary Figure S2B). After 10 min, 10 ml of 2× substrate mix (1000 nM
6 nt U substrate in same buffer as enzyme mix) was dispensed and plates were centrifuged. Two minutes after
dispensing substrate mix, plates were read with a Spark Multimode microplate reader (Tecan) with the follow-
ing settings: Excitation 645 nm (±10), Emission 675 nm (±10), Gain 125, 10 flashes, Z position of 17 500, every
minute for 15 min.
Screen data analysis
The slope of each reaction was determined by linear regression. Residual activity was then calculated by divid-
ing residual activity in the presence of each compound by the median of the control wells without drugs of
each plate. Z-scores were calculated using the standard deviation and median of residual activities for each con-
centration. Plate 24 of the high concentration was omitted from analysis. Z0 factors were calculated for each
plate to determine screen quality according to Zhang et al. [63].
KM and IC50 calculation
First, we calculated the slope of the reaction in the presence of 75 nM nsp15 and a titration of the 6 nt U sub-
strate (0–1000 nM) considering the first 10 min of the reactions by linear regression. Slopes were then used to
calculate Khalf and VMAX by non-linear fitting to an Allosteric sigmoidal equation using GraphPad Prism.
Similarly, we calculated the slope of the reaction in the presence of 75 nM nsp15, 6 nt U substrate (500 nM)
and a titration of NSC95397 considering the first 15 min of the reactions by linear regression. Slopes were then
used to calculate percentage of activity relative to the slope obtained with 0 mM NSC95397. Percent activity for
each log10 of the concentration of NSC95397 (mM) were then used to estimate the IC50 and Hill slopes of
NSC95397 for nsp15 endoribonuclease using GraphPad Prism.
SARS-CoV-2 infectivity assays
Infectivity assays were performed as in the accompanying manuscript (see Zeng et al. [31]). Briefly, VERO E6
cells were grown in 96 well imaging plates and transfected with individual gapmers at 0.5 mM using
Lipofectamine 2000 (Thermofisher). Six hours post transfection, the media was replaced and infected with
SARS-CoV-2 at an MOI of 0.5 PFU/cell and, simultaneously, a titration of NSC95397 was added to different
wells with or without the addition of 0.5 mM remdesivir. Twenty-two hours post-infection, cells were fixed, per-
meabilised and stained for SARS-CoV-2 N-protein using Alexa488-labelled-CR3009 antibody [64] and nuclei
using DRAQ5 (647 nm wavelength). Imaging was performed using a 5× lens in an Opera Phenix high content
screening microscope (PerkinElmer) equipped with the Harmony software. The whole well area was delineated,
and area of Alexa488/N protein and DRAQ5/DNA signals were determined for each well. The Alexa488/N
intensities were normalised to DRAQ5/DNA and to vehicle treated samples.
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